DK3653228T3 - Anti-folr1-immunkonjugatdoseringsregimer - Google Patents

Anti-folr1-immunkonjugatdoseringsregimer Download PDF

Info

Publication number
DK3653228T3
DK3653228T3 DK19199163.7T DK19199163T DK3653228T3 DK 3653228 T3 DK3653228 T3 DK 3653228T3 DK 19199163 T DK19199163 T DK 19199163T DK 3653228 T3 DK3653228 T3 DK 3653228T3
Authority
DK
Denmark
Prior art keywords
immune conjugate
dosage regimes
folr1 immune
conjugate dosage
folr1
Prior art date
Application number
DK19199163.7T
Other languages
English (en)
Inventor
Robert J Lutz
Jose Ponte
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3653228(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of DK3653228T3 publication Critical patent/DK3653228T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK19199163.7T 2013-10-08 2014-10-08 Anti-folr1-immunkonjugatdoseringsregimer DK3653228T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361888337P 2013-10-08 2013-10-08
US201361888365P 2013-10-08 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US201462004815P 2014-05-29 2014-05-29
EP14852834.2A EP3055332B1 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens

Publications (1)

Publication Number Publication Date
DK3653228T3 true DK3653228T3 (da) 2024-07-15

Family

ID=52813740

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14852834T DK3055332T3 (da) 2013-10-08 2014-10-08 Anti-folr1-immunkonjugat-doseringsregimer
DK19199163.7T DK3653228T3 (da) 2013-10-08 2014-10-08 Anti-folr1-immunkonjugatdoseringsregimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14852834T DK3055332T3 (da) 2013-10-08 2014-10-08 Anti-folr1-immunkonjugat-doseringsregimer

Country Status (29)

Country Link
US (3) US20150132323A1 (da)
EP (3) EP4424323A3 (da)
JP (5) JP6463744B2 (da)
KR (7) KR20240027861A (da)
CN (1) CN106164093A (da)
AU (4) AU2014331964C1 (da)
BR (1) BR112016007479A2 (da)
CA (1) CA2926325C (da)
CY (2) CY1122449T1 (da)
DK (2) DK3055332T3 (da)
ES (2) ES2759426T3 (da)
FI (1) FI3653228T3 (da)
HR (2) HRP20240917T1 (da)
HU (2) HUE067367T2 (da)
IL (4) IL298044B2 (da)
LT (2) LT3055332T (da)
MX (2) MX384973B (da)
MY (1) MY174670A (da)
NZ (2) NZ757964A (da)
PL (2) PL3653228T3 (da)
PT (2) PT3653228T (da)
RS (2) RS65798B1 (da)
RU (1) RU2696579C2 (da)
SG (3) SG11201602361UA (da)
SI (2) SI3653228T1 (da)
SM (1) SMT201900694T1 (da)
UA (1) UA119541C2 (da)
WO (1) WO2015054400A2 (da)
ZA (1) ZA201902009B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
CN119185571A (zh) * 2013-05-14 2024-12-27 伊缪诺金公司 抗folr1免疫缀合物给药方案
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
JP6880006B2 (ja) * 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
MX2019013753A (es) * 2017-05-16 2020-07-20 Immunogen Inc Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
CN111655726B (zh) 2017-09-18 2024-06-21 苏特罗生物制药公司 抗叶酸受体α抗体偶联物和其用途
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
JP7623939B2 (ja) 2018-07-09 2025-01-29 マルチチュード インコーポレーテッド 葉酸受容体アルファに特異的な抗体
CN114222756A (zh) 2019-04-29 2022-03-22 伊缪诺金公司 双互补位FR-α抗体和免疫缀合物
EP4347661A4 (en) * 2021-06-04 2025-06-18 ImmunoGen, Inc. TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
WO2023102077A1 (en) * 2021-12-01 2023-06-08 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP2002514193A (ja) * 1996-11-15 2002-05-14 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植のためのコンディショニング
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
US20090162374A1 (en) * 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
EP2281006B1 (en) 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
EP2378876B1 (en) * 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
CA2775806A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
AR080301A1 (es) * 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
US20120207771A1 (en) * 2010-11-05 2012-08-16 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
PL2694106T3 (pl) * 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
KR20150046316A (ko) * 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
EP2983654B1 (en) * 2013-04-08 2025-11-12 BPGbio, Inc. Treatment of cancer using coenzyme q10 combination therapies
CN119185571A (zh) * 2013-05-14 2024-12-27 伊缪诺金公司 抗folr1免疫缀合物给药方案
PT3038650T (pt) * 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
JP6880006B2 (ja) * 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ

Also Published As

Publication number Publication date
HRP20240917T1 (hr) 2024-10-11
EP3653228A1 (en) 2020-05-20
ES2759426T3 (es) 2020-05-11
LT3055332T (lt) 2020-04-10
EP3055332B1 (en) 2019-09-25
JP2019218386A (ja) 2019-12-26
WO2015054400A3 (en) 2015-06-25
JP2024016239A (ja) 2024-02-06
AU2014331964B2 (en) 2018-09-13
PT3653228T (pt) 2024-07-17
KR102639861B1 (ko) 2024-02-22
AU2024201615A1 (en) 2024-04-04
JP2019031568A (ja) 2019-02-28
JP2016534039A (ja) 2016-11-04
AU2020264270B2 (en) 2024-01-18
KR102115217B9 (ko) 2021-12-24
HUE046696T2 (hu) 2020-03-30
HRP20192140T1 (hr) 2020-03-06
NZ757964A (en) 2022-07-01
AU2014331964C1 (en) 2019-10-31
AU2020264270A1 (en) 2020-11-26
IL265586A (en) 2019-05-30
US20240368270A1 (en) 2024-11-07
CY1127391T1 (el) 2026-02-25
SI3055332T1 (sl) 2020-02-28
RU2016114708A3 (da) 2018-07-31
WO2015054400A2 (en) 2015-04-16
US20210155688A1 (en) 2021-05-27
SG11201602361UA (en) 2016-04-28
JP2021178847A (ja) 2021-11-18
HK1226671A1 (en) 2017-10-06
SMT201900694T1 (it) 2020-01-14
SG10202102555TA (en) 2021-04-29
NZ718766A (en) 2020-02-28
KR20240027861A (ko) 2024-03-04
BR112016007479A2 (pt) 2017-09-12
ZA201902009B (en) 2020-10-28
KR20200058592A (ko) 2020-05-27
KR102303874B1 (ko) 2021-09-17
MX2016004411A (es) 2016-07-05
RU2696579C2 (ru) 2019-08-05
PL3055332T3 (pl) 2020-02-28
PL3653228T3 (pl) 2024-11-12
LT3653228T (lt) 2024-07-25
IL313730A (en) 2024-08-01
EP4424323A2 (en) 2024-09-04
UA119541C2 (uk) 2019-07-10
JP7386208B2 (ja) 2023-11-24
EP3055332A4 (en) 2017-05-31
RS65798B1 (sr) 2024-08-30
EP3055332A2 (en) 2016-08-17
JP6581279B2 (ja) 2019-09-25
RS59644B1 (sr) 2020-01-31
CA2926325C (en) 2023-08-01
ES2983055T3 (es) 2024-10-21
IL244772A0 (en) 2016-04-21
KR20210118220A (ko) 2021-09-29
MX2021009222A (es) 2021-09-08
AU2014331964A1 (en) 2016-04-28
AU2018278880A1 (en) 2019-01-03
FI3653228T3 (fi) 2024-07-04
DK3055332T3 (da) 2019-12-09
EP4424323A3 (en) 2024-11-13
EP3653228B1 (en) 2024-05-15
KR20160079797A (ko) 2016-07-06
MX384973B (es) 2025-03-14
SI3653228T1 (sl) 2024-09-30
IL244772B (en) 2019-05-30
KR102115217B1 (ko) 2020-05-26
RU2016114708A (ru) 2017-11-15
IL298044B2 (en) 2024-11-01
KR20230145544A (ko) 2023-10-17
US20150132323A1 (en) 2015-05-14
CN106164093A (zh) 2016-11-23
IL298044A (en) 2023-01-01
KR20220136468A (ko) 2022-10-07
JP6463744B2 (ja) 2019-02-06
MY174670A (en) 2020-05-06
CY1122449T1 (el) 2021-01-27
CA2926325A1 (en) 2015-04-16
HUE067367T2 (hu) 2024-10-28
SG10201907042PA (en) 2019-09-27
IL298044B1 (en) 2024-07-01
KR20210041124A (ko) 2021-04-14
PT3055332T (pt) 2019-12-09

Similar Documents

Publication Publication Date Title
FR25C1038I1 (fr) Conjugue anticorps anti-trop2-medicament
CY1127391T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1
ZA201505656B (en) Antibody drug conjugates
EP2972351A4 (en) IMPROVED TEST PROCEDURES
DK3460054T3 (da) Histidyl-tRNA-syntetase-Fc-konjugater
DK3062849T3 (da) Medikamentadministrationsanordning
UA29910S (uk) Блендер
CL2015003481A1 (es) Conjugados de anticuerpo fármaco
BR112016015105A8 (pt) conjugados var2csa-droga
EP2933279A4 (en) Copolymer
DOS2013000177S (es) Capsulas
PL3287133T3 (pl) Protono-wiążące polimery do podawania doustnego
DK2767269T3 (da) Terapeutisk anordning
EP2993194A4 (en) multiblock
EP3359555A4 (en) DOSIERPLÄNE
DK3079667T3 (da) Farmaceutiske doseringsformer
DK3003401T3 (da) Farmaceutisk præparat
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
HUE046318T2 (hu) Élelmiszer készítmény
HRP20171888T1 (hr) Farmaceutski pripravci
BR112016002795A2 (pt) preparação de glicidol
DE112014002244A5 (de) Infusionslösung
UA29452S (uk) Тостер
DK3071267T3 (da) Lægemiddeladministrationsanordning med ensrettet kobling
UA25711S (uk) Серветка